Olwen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-11-2024
- Paid Up Capital ₹ 0.10 M
as on 09-11-2024
- Company Age 2 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 1711.86%
(FY 2023)
- Profit 188.31%
(FY 2023)
- Ebitda 275.21%
(FY 2023)
- Net Worth 36.29%
(FY 2023)
- Total Assets 1636.35%
(FY 2023)
About Olwen Pharmaceuticals
The Corporate was formerly known as Olwen Pharmatceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ram Prajapat and Swati Prajapat serve as directors at the Company.
- CIN/LLPIN
U24230RJ2022PTC079493
- Company No.
079493
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Feb 2022
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jodhpur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Olwen Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ram Prajapat  | Director | 04-Feb-2022 | Current |
| Swati Prajapat | Director | 04-Feb-2022 | Current |
Financial Performance of Olwen Pharmaceuticals.
Olwen Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1711.86% increase. The company also saw a substantial improvement in profitability, with a 188.31% increase in profit. The company's net worth Soared by an impressive increase of 36.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Olwen Pharmaceuticals?
Unlock access to Olwen Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Olwen Lifesciences Private LimitedActive 10 years 3 monthsRam Prajapat and Swati Prajapat are mutual person
- Bhaskar Green Energy Private LimitedActive 2 years 3 months
Ram Prajapat and Swati Prajapat are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Olwen Pharmaceuticals?
Olwen Pharmaceuticals has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Olwen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Olwen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
